Engineered immune cells take on tough lymphoma in new trial
NCT ID NCT07288879
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new CAR T cell therapy called MB-CART2019.1 in 31 people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, genetically modified to target and kill cancer cells. The main goal is to see how many patients' tumors shrink or disappear one month after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR T cell therapy (MB-CART2019.1)
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat DLBCL that has not responded to standard therapies.
- What could go wrong
- This is a small, early-phase study (31 participants) with no control group. CAR T therapy can cause serious side effects like cytokine release syndrome. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAR-T CELL THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Juntendo University Hospital
NOT_YET_RECRUITINGTokyo, 113-8431, Japan
-
Keio University Hospital
NOT_YET_RECRUITINGTokyo, 160-8582, Japan
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
-
Tokyo Metropolitan Komagome Hospital
RECRUITINGTokyo, 113-8677, Japan
-
Toranomon Hospital
NOT_YET_RECRUITINGTokyo, 105-8470, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Four-Pronged attack beat brain lymphoma?
- Can a new drug combo outsmart resistant lymphomas?
- Can a targeted drug boost standard chemo for aggressive lymphoma?